Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Holding LXRX?
Track your performance easily
LXRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.92 - $3.73
Previous Close$1.64
Volume2.63M
Average Volume (3M)2.83M
Market Cap
$592.85M
Enterprise Value$382.38M
Total Cash (Recent Filing)$309.96M
Total Debt (Recent Filing)$99.50M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 06, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding361,492,295
10 Day Avg. Volume1,810,372
30 Day Avg. Volume2,830,655
Standard Deviation0.34
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.48
Price to Sales (P/S)160.84
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue194.70
Enterprise Value/Gross Profit341.72
Enterprise Value/Ebitda-9.07
Forecast
1Y Price Target
$8.33Price Target Upside392.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Lexicon Pharmaceuticals News
PremiumCompany Announcements
Lexicon Pharmaceuticals Announces Executive Leadership ChangesBulls Say, Bears Say
Bulls Say
Clinical TrialsINPEFA demonstrates a reduced risk of cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in patients with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Product DevelopmentMultiple sites have been opened for patient recruitment in the SONATA Phase 3 study evaluating sotagliflozin in hypertrophic cardiomyopathy patients, with strong site activation and investigator enthusiasm reported.
Strategic InitiativesLexicon's strategic cost-saving initiatives are expected to yield $40 million in savings, which will fund potential commercial efforts for Zynquista and ongoing trials efficiently.
Bears Say
Market CompetitionPrescription rates and sales could be constrained or delayed considering that heart failure is a crowded space among the big players.
Regulatory ConcernsThe FDA raised concerns regarding increased risk of developing DKA with sotagliflozin treatment.
Sales Performance2Q24 Inpefa sales were $1.6M, below our $3.0M and consensus $3.5M estimates.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.92 and its highest was $3.73 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Currently, no data Available
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.177 by $0.007.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -$0.16.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 361,492,300 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.177. Following the earnings report the stock price went down -15.842%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Among the largest hedge funds holding Lexicon Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Lexicon Pharmaceuticals’s shares valued at N/A.
---
Lexicon Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (392.90% Upside)
$8.33 (392.90% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 427.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.87%
12-Months-Change
Fundamentals
Return on Equity
-94.10%
Trailing 12-Months
Asset Growth
17.88%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
---
LXRX Earnings Call
Q2 2024
0:00 / 0:00
---
LXRX Stock 12 Month Forecast
Average Price Target
$8.33
▲(392.90% Upside)
Technical Analysis
Best Analysts Covering LXRX
1 Year
1 Year Success Rate
6/20 ratings generated profit
1 Year Average Return
-8.34%
reiterated a buy rating 5 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -8.34% per trade.
---